Loading…
H.R. 4299119th CongressIn committeeLatest action Jul 7, 2025Decoded by AI · checked against the record
Official title: Protecting Patient Access to Cancer and Complex Therapies Act
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
Instead of selling drugs at a lower price upfront, manufacturers could charge full price and pay Medicare back the difference later.
50-second read · 5 questions answered below
This bill changes how drug companies deliver price reductions on certain high-cost drugs, like cancer treatments given in a doctor's office or hospital. Instead of charging the lower negotiated price at the point of sale, manufacturers could charge their standard price and send the difference to Medicare as a rebate afterward. Patients would still pay out-of-pocket costs based on the lower negotiated price.
Drug manufacturers that take part in Medicare's drug price negotiation program are directly affected. Medicare patients who receive these high-cost drugs in clinical settings, such as cancer treatment, are also affected.
This changes when and how the government collects the savings from negotiated drug prices. The rebate money manufacturers pay would go into the Medicare trust fund.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.